Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Conatus names executive VP, clinical development

This article was originally published in Scrip

Executive Summary

Conatus Pharmaceuticals, a biotechnology company focused on the development and commercialization of medicines to treat liver disease, has named Dr David T Hagerty executive vice-president of clinical development. He will oversee the company's medical activities including clinical development, clinical operations, regulatory affairs, biostatistics, quality assurance and drug safety. Dr Hagerty has been an independent consultant in clinical development since April 2013. Prior to this he was senior vice-president and chief medical officer at Ardea Biosciences.

Advertisement

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC026529

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel